<DOC>
	<DOCNO>NCT01280487</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) preliminary efficacy daily oral dos ZSTK474 , oral phosphatidylinositol 3-kinase ( PI3K ) inhibitor , subject advance solid malignancy .</brief_summary>
	<brief_title>A Safety Study Oral ZSTK474 Patients With Cancer</brief_title>
	<detailed_description />
	<criteria>1 . Male female ≥18 year age ; 2 . Histologicallyconfirmed advanced ( metastatic unresectable ) solid tumor available therapy effective ; 3 . ECOG performance status score ≤2 expect survival &gt; 8 week ; 4 . Recovered toxicity prior chemotherapy , radiotherapy , cancer therapy ; toxicity must determine Grade 2 ( assess use NCI CTCAE v4.0 ) . 5 . Adequate blood count hemoglobin ( Hgb ) ≥9.0 mg/dL , absolute neutrophil count ( ANC ) &gt; 1,500/mm3 , platelet ≥100,000/mm3 ( without transfusion support ) ; 6 . Subjects willing able provide write informed consent . In expanded cohort MTD : Subjects must willing undergo mandatory biopsy tumor tissue twice first cycle ( dose ) must tumor tissue location accessible incisional biopsy superficial lesion percutaneous core needle biopsy outpatient basis without undue risk subject . 1 . Women pregnant breastfeeding ; 2 . Men woman reproductive potential willing use acceptable mean contraception study drug additional 90 day last dose study drug ; 3 . Body Mass Index ( BMI ) ≥30 kg/m2 ; 4 . Have primary central nervous system ( CNS ) tumor untreated/uncontrolled CNS metastasis ; Note : Subjects stable/controlled CNS metastasis may enrol ( i.e. , CNS lesions stable size least one month subject steroid anticonvulsant ) . 5 . Have receive investigational interventional agent within 4 week prior start dose ZSTK474 ; 6 . Are receive concurrent antitumor chemotherapy , radiotherapy , immunotherapy receive noninvestigational agent within previous 4 week 5halflives ( whichever longer ) prior start dose ZSTK474 ; 7 . Are able willing comply study procedure , include study visit schedule ; 8 . Have previously treat phosphatidylinositol 3 kinase ( PI3K ) inhibitor ; 9 . Have serious significant intercurrent illness underlie disease , : 1 . Diabetes 2 . Gastrointestinal disorder 3 . Hepatic : AST ALT &gt; 2.5 x ULN ( &gt; 5.0 x ULN liver metastasis ) serum bilirubin &gt; 1.5 x ULN ; 4 . Renal ( acute chronic renal disease eGFR &lt; 55 mL/min ) 5 . Cardiovascular : Uncontrolled hypertension blood pressure &gt; 140/90 mmHg ; Symptomatic congestive heart failure ; Myocardial infarction within past 6 month ; Unstable angina pectoris ; Cardiac arrhythmia ; Congenital long QT syndrome ; QTc &gt; 450 msec men &gt; 470 msec woman . 6 . Other : Known diagnosis HIV infection ; Other ongoing active infection ; Psychiatric illness , substance abuse social situation would preclude study compliance . Other serious concurrent illness would preclude assessment drug effect ; PT/PTT ) /APTT/INR &gt; ULN subject anticoagulant ; INR &gt; 1.5 x ULN subject low dose warfarin . 10 . Current treatment follow drug : antiseizure medication ; therapeutic anticoagulant dose warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ZSTK474</keyword>
	<keyword>PI3K inhibitor</keyword>
</DOC>